Nimble Is Looking for 850,000 to Complete Preclinical Trials

Nimble is seeking capital to launch its medical project. The Catalan startup, which has created a cardiac stent monitor using microwaves, will open a financing round of $867,000 (€850,000) in the next few days, according to Oriol Iborra, CEO of Nimble.

With its technology, the Spanish company aims to prevent possible heart disease in a non-invasive way. This will make it possible to implement early treatments and avoid serious complications, as well as to identify and optimize medical procedures.

With the capital raised, Nimble will complete the preclinical testing phase, incorporate regulation and hire personnel. In addition, the company intends to test its tool within the hospital setting, specifically through a pilot program led by the Germans Trias i Pujol Hospital (Hgtp) in Badalona. The startup plans to start marketing its devices in 2025.

If you want to find more details about nimble and to read the latest financial headlines in the world, download for free our companion app Born2Invest.

Nimble Diagnostics was created in the university network, from the Igtp, the UPC, and the UB

Stents are medical devices capable of restoring the flow of blood or other fluids. These cannulas are used to treat cardiovascular diseases and thus prevent both myocardial infarction and treat post-infarction symptoms.

The business opportunity comes from the obsolescence of stents, since once implanted, they can become clogged or damaged. Even so, patient symptoms usually appear when these devices have already lost 90% of their functionality.

In these cases, an invasive procedure called angiography must be performed, which entails “considerable economic expense,” according to Iborra. In addition, this procedure would have a greater impact on the patient’s body.

The company plans to start marketing its devices from 2025 

In 2021, the Catalan company has already raised half a million euros from CaixaImpulse, FIS, the Marató de TV3 and the Premi societat catalana. The company’s origins lie in the university network, specifically at the Germans Trias i Pujol Health Sciences Research Institute (Igtp), the Polytechnic University of Catalonia (UPC), and the University of Barcelona (UB).

In addition to Oriol Iborra, the founding team includes Susana Amorós, Carolina Gàlvez, Oriol Rodríguez and Antoni Bayés, as well as researchers Joan Manel O’Callaghan, Lluís Jofre and Jordi Romeu, from the UPC, and Javier Tejada, from the UB.

__

(Featured image by geralt via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.